中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Research advances in early screening and diagnosis of hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.06.033
Research funding:

Tianjin Health Science and Technology Project Key Disciplines (TJWJ2022XK034);

Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-059B);

Key Scientific Research Project of Integrated Traditional Chinese and Western Medicine of Tianjin Health Commission (2021022)

More Information
  • Corresponding author: XU Liang, xuyangliang2004@sina.com (ORCID: 0000-0001-5441-1217)
  • Received Date: 2022-09-30
  • Accepted Date: 2022-10-24
  • Published Date: 2023-06-20
  • For the high-risk population, early screening and diagnosis are important measures to achieve good control of liver cancer and reduce the burden of liver cancer, and determining the high-risk population of liver cancer and formulating appropriate liver cancer screening strategies are the key to realizing the early screening and diagnosis of liver cancer. The risk assessment model for liver cancer is an important method for rapid and convenient identification of the high-risk population of liver cancer. Based on the risk stratification of liver cancer, the methods such as imaging technology, serological markers, liquid biopsy, metabolomics, and glycomics can be used for accurate early screening and diagnosis of liver cancer, so as to achieve the goal of early treatment.

     

  • [1]
    SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
    [2]
    ZHOU M, WANG H, ZENG X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. DOI: 10.1016/S0140-6736(19)30427-1.
    [3]
    General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.

    国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
    [4]
    XIAO J, WANG F, WONG NK, et al. Global liver disease burdens and research trends: Analysis from a Chinese perspective[J]. J Hepatol, 2019, 71(1): 212-221. DOI: 10.1016/j.jhep.2019.03.004.
    [5]
    BRUIX J, CHAN SL, GALLE PR, et al. Systemic treatment of hepatocellular carcinoma: An EASL position paper[J]. J Hepatol, 2021, 75(4): 960-974. DOI: 10.1016/j.jhep.2021.07.004.
    [6]
    HEIMBACH JK, KULIK LM, FINN RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 358-380. DOI: 10.1002/hep.29086.
    [7]
    KUDO M, KAWAMURA Y, HASEGAWA K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update[J]. Liver Cancer, 2021, 10(3): 181-223. DOI: 10.1159/000514174.
    [8]
    VOGEL A, CERVANTES A, CHAU I, et al. Correction to: "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"[J]. Ann Oncol, 2019, 30(5): 871-873. DOI: 10.1093/annonc/mdy510.
    [9]
    SHARMA SA, KOWGIER M, HANSEN BE, et al. Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis[J]. J Hepatol, 2018, 68(1): 92-99. DOI: 10.1016/j.jhep.2017.07.033.
    [10]
    ZHANG H, ZHU J, XI L, et al. Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study[J]. World J Surg Oncol, 2019, 17(1): 75. DOI: 10.1186/s12957-019-1619-3.
    [11]
    YANG HI, YUEN MF, CHAN HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score[J]. Lancet Oncol, 2011, 12(6): 568-574. DOI: 10.1016/S1470-2045(11)70077-8.
    [12]
    PAPATHEODORIDIS G, DALEKOS G, SYPSA V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy[J]. J Hepatol, 2016, 64(4): 800-806. DOI: 10.1016/j.jhep.2015.11.035.
    [13]
    LEE HW, KIM SU, PARK JY, et al. External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy[J]. Liver Int, 2019, 39(9): 1624-1630. DOI: 10.1111/liv.14129.
    [14]
    LAMBRECHT J, PORSCH-ÖZÇÜRÜMEZ M, BEST J, et al. The APAC score: a novel and highly performant serological tool for early diagnosis of hepatocellular carcinoma in patients with liver cirrhosis[J]. J Clin Med, 2021, 10(15): 3392. DOI: 10.3390/jcm10153392.
    [15]
    LI XH, HAO X, DENG YH, et al. The aMAP score was used to assess the risk of liver cancer among people with chronic liver disease in primary hospitals[J]. Chin J Hepatol, 2021, 29(4): 332-337. DOI: 10.3760/cma.j.cn501113-20210329-00144.

    李秀华, 郝新, 邓永红, 等. 应用aMAP评分评估基层医院慢性肝病人群的肝癌发生风险[J]. 中华肝脏病杂志, 2021, 29(4): 332-337. DOI: 10.3760/cma.j.cn501113-20210329-00144.
    [16]
    KIM HY, LAMPERTICO P, NAM JY, et al. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B[J]. J Hepatol, 2022, 76(2): 311-318. DOI: 10.1016/j.jhep.2021.09.025.
    [17]
    HARRIS PS, HANSEN RM, GRAY ME, et al. Hepatocellular carcinoma surveillance: An evidence-based approach[J]. World J Gastroenterol, 2019, 25(13): 1550-1559. DOI: 10.3748/wjg.v25.i13.1550.
    [18]
    CHOI J, KIM GA, HAN S, et al. Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma[J]. Hepatology, 2019, 69(5): 1983-1994. DOI: 10.1002/hep.30233.
    [19]
    HUGHES DM, BERHANE S, EMILY DE GROOT CA, et al. Serum levels of α-fetoprotein increased more than 10 years before detection of hepatocellular carcinoma[J]. Clin Gastroenterol Hepatol, 2021, 19(1): 162-170. e4. DOI: 10.1016/j.cgh.2020.04.084.
    [20]
    YAN YF, WANG YT, ZHU C, et al. Meta analysis of the accuracy of liver cancer screening technology[J]. Chin J Evid-Based Med, 2018, 18(5): 418-427. DOI: 10.7507/1672-2531.201802055.

    严永锋, 王宇婷, 朱陈, 等. 肝癌筛查技术准确性的Meta分析[J]. 中国循证医学杂志, 2018, 18(5): 418-427. DOI: 10.7507/1672-2531.201802055.
    [21]
    ROBERTS LR, SIRLIN CB, ZAIEM F, et al. Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis[J]. Hepatology, 2018, 67(1): 401-421. DOI: 10.1002/hep.29487.
    [22]
    NADAREVIC T, COLLI A, GILJACA V, et al. Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease[J]. Cochrane Database Syst Rev, 2022, 5(5): CD014798. DOI: 10.1002/14651858.CD014798.pub2.
    [23]
    GAO F, WEI Y, ZHANG T, et al. New liver MR imaging hallmarks for small hepatocellular carcinoma screening and diagnosing in high-risk patients[J]. Front Oncol, 2022, 12: 812832. DOI: 10.3389/fonc.2022.812832.
    [24]
    LV K, ZHAI H, JIANG Y, et al. Prospective assessment of diagnostic efficacy and safety of SonazoidTM and SonoVue® ultrasound contrast agents in patients with focal liver lesions[J]. Abdom Radiol (NY), 2021, 46(10): 4647-4659. DOI: 10.1007/s00261-021-03010-1.
    [25]
    FRAQUELLI M, NADAREVIC T, COLLI A, et al. Contrast- enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease[J]. Cochrane Database Syst Rev, 2022, 9(9): CD013483. DOI: 10.1002/14651858.CD013483.pub2.
    [26]
    ZHANG L, GU J, LI Y, et al. Clinical value study on contrast-enhanced ultrasound combined with enhanced CT in early diagnosis of primary hepatic carcinoma[J]. Contrast Media Mol Imaging, 2022, 2022: 7130533. DOI: 10.1155/2022/7130533.
    [27]
    LIU D, LIU F, XIE X, et al. Accurate prediction of responses to transarterial chemoembolization for patients with hepatocellular carcinoma by using artificial intelligence in contrast-enhanced ultrasound[J]. Eur Radiol, 2020, 30(4): 2365-2376. DOI: 10.1007/s00330-019-06553-6.
    [28]
    YASAKA K, AKAI H, ABE O, et al. Deep learning with convolutional neural network for differentiation of liver masses at dynamic contrast-enhanced CT: a preliminary study[J]. Radiology, 2018, 286(3): 887-896. DOI: 10.1148/radiol.2017170706.
    [29]
    HU HT, WANG W, CHEN LD, et al. Artificial intelligence assists identifying malignant versus benign liver lesions using contrast-enhanced ultrasound[J]. J Gastroenterol Hepatol, 2021, 36(10): 2875-2883. DOI: 10.1111/jgh.15522.
    [30]
    ZHOU JM, WANG T, ZHANG KH. AFP-L3 for the diagnosis of early hepatocellular carcinoma: A meta-analysis[J]. Medicine (Baltimore), 2021, 100(43): e27673. DOI: 10.1097/MD.0000000000027673.
    [31]
    CHOI J, KIM GA, HAN S, et al. Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma[J]. Hepatology, 2019, 69(5): 1983-1994. DOI: 10.1002/hep.30233.
    [32]
    BEST J, BECHMANN LP, SOWA JP, et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis[J]. Clin Gastroenterol Hepatol, 2020, 18(3): 728-735. e4. DOI: 10.1016/j.cgh.2019.11.012.
    [33]
    CAVIGLIA GP, CIRUOLO M, ABATE ML, et al. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist ii and glypican-3 for the detection and prediction of hepatocellular carcinoma in patients with cirrhosis of viral Etiology[J]. Cancers (Basel), 2020, 12(11): 3218. DOI: 10.3390/cancers12113218.
    [34]
    SAMMAN BS, HUSSEIN A, SAMMAN RS, et al. Common sensitive diagnostic and prognostic markers in hepatocellular carcinoma and their clinical significance: a Review[J]. Cureus, 2022, 14(4): e23952. DOI: 10.7759/cureus.23952.
    [35]
    SHAKER MK, ATTIA FM, HASSAN AA, et al. Evaluation of golgi protein 73 (GP73) as a potential biomarkers for hepatocellular carcinoma[J]. Clin Lab, 2020, 66(8): 190911. DOI: 10.7754/Clin.Lab.2020.190911.
    [36]
    YAMASHITA T, KOSHIKAWA N, SHIMAKAMI T, et al. Serum laminin γ2 monomer as a diagnostic and predictive biomarker for hepatocellular carcinoma[J]. Hepatology, 2021, 74(2): 760-775. DOI: 10.1002/hep.31758.
    [37]
    CHEN L, ZHANG H, JIANG B. Diagnostic value of combined detection of serum AFP, GGTI Ⅱ, AFU and DCP in liver cancer[J]. J Mol Diagn Ther, 2022, 14 (8): 1283-1286, 1291. DOI: 10.3969/j.issn.1674-6929.2022.08.006.

    陈琳, 张恒, 江斌. 血清AFP、GGTIⅡ、AFU和DCP联合检测对肝癌的诊断价值[J]. 分子诊断与治疗杂志, 2022, 14(8): 1283-1286, 1291. DOI: 10.3969/j.issn.1674-6929.2022.08.006.
    [38]
    EUN JW, JANG JW, YANG HD, et al. Serum proteins, HMMR, NXPH4, PITX1 and THBS4; a panel of biomarkers for early diagnosis of hepatocellular carcinoma[J]. J Clin Med, 2022, 11(8): 2128. DOI: 10.3390/jcm11082128.
    [39]
    CHEN L, ABOU-ALFA GK, ZHENG B, et al. Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients[J]. Cell Res, 2021, 31(5): 589-592. DOI: 10.1038/s41422-020-00457-7.
    [40]
    CHALASANI NP, RAMASUBRAMANIAN TS, BHATTACHARYA A, et al. A novel blood-based panel of methylated dna and protein markers for detection of early-stage hepatocellular carcinoma[J]. Clin Gastroenterol Hepatol, 2021, 19(12): 2597-2605. e4. DOI: 10.1016/j.cgh.2020.08.065.
    [41]
    ZHOU J, YU L, GAO X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29(36): 4781-4788. DOI: 10.1200/JCO.2011.38.2697.
    [42]
    LI YS, YANG ZG, CHEN Y, et al. Differential expression profile of cyclic RNA in serum exocrine bodies of hepatocellular carcinoma and its clinical significance[J]. J Hepatopancreatobiliary Surg, 2022, 34(5): 283-287. DOI: 10.11952/j.issn.1007-1954.2022.05.006.

    李叶晟, 杨宗国, 陈晹, 等. 肝癌血清外泌体环状RNA表达谱差异及其临床意义[J]. 肝胆胰外科杂志, 2022, 34(5): 283-287. DOI: 10.11952/j.issn.1007-1954.2022.05.006.
    [43]
    Large scale prospective cohort study data of early screening liquid biopsy for liver cancer[EB/OL]. [2021-09-01]. https://www.genetronhealth.com/product_detail.html.

    肝癌早筛液体活检大规模前瞻性队列研究数据[EB/OL]. [2021-09-01]. https://www.genetronhealth.com/product_detail.html.
    [44]
    LIN N, LIN Y, XU J, et al. A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma[J]. Hepatol Commun, 2022, 6(7): 1753-1763. DOI: 10.1002/hep4.1918.
    [45]
    ZHAN S, YANG P, ZHOU S, et al. Serum mitochondrial tsRNA serves as a novel biomarker for hepatocarcinoma diagnosis[J]. Front Med, 2022, 16(2): 216-226. DOI: 10.1007/s11684-022-0920-7.
    [46]
    LI Y, LI R, CHENG D, et al. The potential of CircRNA1002 as a biomarker in hepatitis B virus-related hepatocellular carcinoma[J]. Peer J, 2022, 10: e13640. DOI: 10.7717/peerj.13640.
    [47]
    STEPIEN M, KESKI-RAHKONEN P, KISS A, et al. Metabolic perturbations prior to hepatocellular carcinoma diagnosis: Findings from a prospective observational cohort study[J]. Int J Cancer, 2021, 148(3): 609-625. DOI: 10.1002/ijc.33236.
    [48]
    WANG SF, BAI ZF, YANG X, et al. Determination of serum metabolic group in patients with hepatocellular carcinoma by UPLC-QTOF-MS/MS technique[J]. Chin J Pharmacol Toxicol, 2020, 34(12): 918-929. DOI: 10.3867/j.issn.1000-3002.2020.12.004.

    王淑凤, 柏兆方, 杨馨, 等. 应用UPLC-QTOF-MS/MS技术测定肝细胞癌患者血清代谢组[J]. 中国药理学与毒理学杂志, 2020, 34(12): 918-929. DOI: 10.3867/j.issn.1000-3002.2020.12.004.
    [49]
    LIU J, GENG W, SUN H, et al. Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma[J]. Gut, 2022, 71(6): 1203-1213. DOI: 10.1136/gutjnl-2021-325189.
    [50]
    YANG T, WANG Y, DAI W, et al. Increased B3GALNT2 in hepatocellular carcinoma promotes macrophage recruitment via reducing acetoacetate secretion and elevating MIF activity[J]. J Hematol Oncol, 2018, 11(1): 50. DOI: 10.1186/s13045-018-0595-3.v
    [51]
    CONG M, OU X, HUANG J, et al. A predictive model using n-glycan biosignatures for clinical diagnosis of early hepatocellular carcinoma related to hepatitis B virus[J]. OMICS, 2020, 24(7): 415-423. DOI: 10.1089/omi.2020.0055.
  • Relative Articles

    [1]Professional Committee on Clinical Precision Medicine, Chinese Medical Doctor Association. Expert consensus on the molecular diagnosis of early-stage pancreatic cancer (2023 edition)[J]. Journal of Clinical Hepatology, 2024, 40(3): 473-477. doi: 10.12449/JCH240306
    [2]Xichen LIU, Yiying WANG, Manman TONG, Junjie QIN. Biomarkers for the early diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(1): 176-179. doi: 10.3969/j.issn.1001-5256.2021.01.038
    [3]Chuanshang HUO, Huijuan FENG, Zhi YE, Ying LIN, Li CHEN, Fei PENG, Lijuan LIU. Value of serum autophagy-related protein 7 in diagnosis of HBV-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(10): 2327-2331. doi: 10.3969/j.issn.1001-5256.2021.10.014
    [4]Zhou Yan, Ning Bo. Application of abnormal cell-free DNA methylation in pancreatic juice in the early diagnosis of pancreatic cancer[J]. Journal of Clinical Hepatology, 2020, 36(9): 2145-2148. doi: 10.3969/j.issn.1001-5256.2020.09.054
    [5]Li ShuHuan, Han JiWu. Inhibitory effect of fibroblast growth factor-21 on the carcinogenesis of L02 cells induced by diethylnitrosamine[J]. Journal of Clinical Hepatology, 2018, 34(2): 321-326. doi: 10.3969/j.issn.1001-5256.2018.02.020
    [6]Luo XinChen, Zhou YouQian. Increasing early diagnosis of primary liver cancer by improving the compliance with regular screening in the high-risk population[J]. Journal of Clinical Hepatology, 2018, 34(8): 1788-1792. doi: 10.3969/j.issn.1001-5256.2018.08.044
    [7]Zhao YunSheng, Zhang LiNa, Huo LiJing, Pei Liu, Li QiuPing, Li HongChen, Jin Liang. Clinical value of fucosylated Golgi protein 73 in differential diagnosis of small hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(8): 1707-1711. doi: 10.3969/j.issn.1001-5256.2018.08.023
    [8]Chen MinHua, Wu Wei. Value of contrast-enhanced ultrasound in early diagnosis of liver cancer and radiofrequency ablation treatment[J]. Journal of Clinical Hepatology, 2017, 33(7): 1211-1213. doi: 10.3969/j.issn.1001-5256.2017.07.002
    [9]Liu Xu, Guo XiaoZhong. Early diagnosis of pancreatic cancer[J]. Journal of Clinical Hepatology, 2016, 32(5): 864-866. doi: 10.3969/j.issn.1001-5256.2016.05.008
    [10]Wang Ting, Liu Mei, Dong Lei, Duan ZhongPing. Application of tumor-associated antigens and their autoantibodies in early diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(7): 1418-1421. doi: 10.3969/j.issn.1001-5256.2016.07.047
    [11]Zhu Chen, Sun YuanYuan, Jin Yan. Values of serum AFP, GGTⅡ and GP73 in diagnosis of primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(10): 1064-1066. doi: 10.3969/j.issn.1001-5256.2014.10.022
    [12]Qu YaChao, LYU Jun. Research progress in serum microRNA detection for diagnosis of hepatocellular carcinoma [J]. Journal of Clinical Hepatology, 2014, 30(3): 228-232. doi: 10.3969/j.issn.1001-5256.2014.03.008
    [13]Guo XiaoZhong, Liu Xu. Discussion of difficult problems of early diagnosis of pancreatic cancer[J]. Journal of Clinical Hepatology, 2014, 30(8): 734-736. doi: 10.3969/j.issn.1001-5256.2014.08.008
    [14]Gao HaiFeng. Value of combined detection of serum AFP and GP73 in early diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(7): 660-662. doi: 10.3969/j.issn.1001-5256.2014.07.022
    [15]Zhu MingYu, Chen Jie, Zhang XinXin. Research advances in serum biomarkers for early diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(10): 1091-1093. doi: 10.3969/j.issn.1001-5256.2014.10.029
    [16]Li HaiPing, Gao Bo, Yu ZongTao, Liu JiuBo, Zhang JiCai. Significance of detection of multigene methylation in liver cancer tissue for early diagnosis of liver cancer[J]. Journal of Clinical Hepatology, 2013, 29(8): 624-626. doi: 10.3969/j.issn.1001-5256.2013.08.018
    [17]Yang YongPing. Current perspectives in preventive and therapeutic strategies for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2013, 29(1): 1-4.
    [18]Li ZhaoShen. Status and prospects of early diagnosis of pancreatic cancer[J]. Journal of Clinical Hepatology, 2010, 26(5): 451-453+458.
  • Cited by

    Periodical cited type(11)

    1. 石玥昕,商娜,乔丽颖,尚书,席云峰. 2016—2018年内蒙古自治区肝癌高危人群筛查依从性及影响因素分析. 中国肿瘤. 2025(01): 58-66 .
    2. 刘月,彭双,谭黎黎. 恩施地区成年居民肝癌高危现状及相关因素调查. 华南预防医学. 2025(02): 198-201 .
    3. 宋慧娟,徐振华,何东宁. 载脂蛋白C1表达对人肝癌HepG2细胞增殖和凋亡的影响及其机制. 吉林大学学报(医学版). 2024(01): 128-135 .
    4. 冯齐齐,郭道宁,刘红佶,熊敏. 肝细胞癌超声特征与病情严重程度及抑癌基因PTEN和Tg737表达的关系探究. 现代消化及介入诊疗. 2024(02): 231-234 .
    5. 任爱华,董彦伯,苗润芝,吕俞娇,刘岩峰. 灵芝酸A对非小细胞肺癌PC9细胞糖酵解及其关键限速酶的影响. 吉林大学学报(医学版). 2024(03): 682-688 .
    6. 杨晢铭,李佳荫,刘丹,宋海旭,张效林,闫承慧. 生物信息学分析揭示胃癌与肝癌共同差异基因表达研究. 临床军医杂志. 2024(07): 666-670 .
    7. 闫飞,胡江英,凤潇翔,林丽,张娜,朱晓颖. 正念减压疗法结合术后早期活动对行腹腔镜下肝癌根治术患者康复质量的影响. 中西医结合护理(中英文). 2024(08): 21-24 .
    8. 夏冬东,汪檬檬,刘云杰,史小英,赵莲,娄延举,武岳,王恩鑫. 比较8个不同肝癌分期系统对经肝动脉化疗栓塞术肝癌患者生存预测价值. 临床军医杂志. 2024(11): 1106-1112 .
    9. 董华. 莫迪司增强及延时扫描技术在肝脏肿瘤诊断中的应用. 西藏医药. 2024(06): 57-58 .
    10. 顾永鹏,刘洁,朱贞宝,吴迪,谢传明,张雷达. 核孔蛋白43在肝细胞癌组织中的表达及其对患者预后和肝癌细胞增殖与迁移的影响. 中华消化外科杂志. 2024(11): 1437-1444 .
    11. 关钊钰,王建花,赵致平. 3.0T MRI对碳离子治疗原发性肝癌后的近中期动态研究. 中国医药科学. 2023(16): 165-169 .

    Other cited types(1)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Article Metrics

    Article views (925) PDF downloads(158) Cited by(12)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return